Long term effect ogf thiazides on bone mass in women with hypercalciuric nephrolithiasis
Abstract
Introduction: Decreased bone mineral density and increased prevalence of bone fractures have been found in patients with idiopathic hypercalciuria. It is not yet clear if thiazide treatment prevent these events. Methods: We retrospectively evaluated bone mass and biochemical markers of bone turnover in response to thiazide therapy in 52 consecutive female patients with idiopathic hypercalciuria and nephrolithiasis. Patients were divided in two subgroups according to their menopausal status: 25 were pre-menopausal (Group I) and 27 were postmenopausal (Group II). Results: Osteoporosis was found in 12 patients at baseline, 9 at the lumbar spine and 6 at the femoral neck. Two were pre-menopausal and 10 were postmenopausal. Patients with osteoporosis were analyzed separately (Group III). There was a significant and persistent reduction in urinary calcium with preservation of bone mass in all the groups after a median follow-up of 51 months. Few adverse effects were found using low doses of hydrochlorothiazide/amiloride. Only in the group III we found a statistically significant an increase in BMD at the lumbar spine of 9.5% and an increase in BMD at femoral neck of 4.4% that did not reach statistical significance. Conclusions: We conclude that correction of hypercalciuria during long term treatment with low-dose hydrochlorothiazide//amiloride in women with nephrolithiasis prevents bone loss and in those with osteoporosis can lead to a significant increase in bone mineral density at the lumbar spine. Few adverse effects were seen during treatment and no interruption of therapy was necessary.References
Zanchetta JR, Rodriguez G, Negri AL, Del Valle E, Spivacow FR. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron. 1996;73(4):557-60.
Heilberg IP, Weisinger JR. Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens 2006;15(4):394-402.
Weisinger JR. New insights into the pathogenesis of idiopathic hypercalciuria: The role of bone. Kidney Int. 1996;49(5):1507-18.
Giannini S, Nobile M, Sartori L, Calò L, Tasca A, Dalle Carbonare L, et al. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol. 1998;50(2):94-100.
Bataille P, Achard JM, Fournier A, Boudailliez B, Westeel PF, El Esper N, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int. 1991;39(6):1193-205.
Borghi L, Meschi T, Guerra A, Maninetti L, Pedrazzoni M, Marcato A, et al. Borghi L. Meschi T. Guerra A et al. Vertebral mineral content in diet-dependent and diet-independent hypercalciuria. J Urol. 1991 Nov;146(5):1334-8.
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999;55(1):234-43.
Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996;49:115-119.
Lauderdale DS, Thisted RA, Wen M, Favus MJ. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res. 2001;16:1893-8.
Steiniche T, Mosekilde L, Christensen MS, Melsen F. A histomorphometry determination of iliac bone remodeling in patients with recurrent bone formation an idiopathic hypercalciuria. APMIS. 1989;97(1-6):309-16.
Malluche HH. Tschoepe HH. Ritz WE. Massry SG: Abnormal bone histology in idiopathic hypercalciuria. J.Clin Endocrinol Metab 1980; 50: 654.
Jaeger P, Lippuner K, Hug C. Low bone mass in idiopathic renal stone formers: magnitude and Significance. J Bone Miner Res. 1994;9:1525-32.
Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Carvalho AB, Lobao R, et al. Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 1998;79:430-7.
Rico H, Revilla M, Villa LF, Arribas I, Alvarez de Buergo M. A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Miner Electrolyte Metab. 1993;19:337-42.
Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hipercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine. 2004;71:51-5.
Lalande A, Roux S, Denne MA, Stanley ER, Schiavi P, Guez D, et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res. 2001;16(2):361-70.
Transbøl I, Christensen MS, Jensen GF, Christiansen C, McNair P. Thiazide for the postponement of postmenopausal bone loss. Metabolism. 1982;31(4):383-6.
Wasnich RD, Davis JW, He YF, Petrovich H, Ross PD. A randomized double-masked. placebo-controlled trial of chlorthalidone and bone loss in
elderly women. Osteoporosis Int. 1995;5:247-51.
La Croix AZ, Ott SM, Ichikawa I, Scholes D, Barlow WE. Low dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized double-blind. placebo controlled trial. Ann Intern Med. 2000;133:516-26.
Costanzo LS, Weiner IM. On the hypocalciuric action of chlorothiazide. J Clin Invest. 1974;54:628-3.
Jang HR, Kim S, Heo NJ, Lee JH, Kim HS, Nielsen S, et al. Effects of thiazide on the expression of TRPV5, calbindin-D28K, and sodium transporters in hypercalciuric rats. J Korean Med Sci. 2009;24 Suppl:S161-9.
Qadri YJ, Song Y, Fuller CM, Benos DJ. Amiloride docking to acid-sensing ion channel-1. J Biol Chem. 2010;285(13):9627-35.
Bataille P, Fardellone P, Ghazali A, Cayrolle G, Hottelart C, Achard JM, et al. Pathophysiology and treatment of idiopathic hypercalciuria. Curr Opin Rheumatol. 1998;10(4):373-88.
Peris P, Guañabens N, Monegal A, Suris X, Alvarez L, Martinez de Osaba MJ, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;34(10):936-41.
Preminger GM, Pak CY. Eventual attenuation of hypercalciuric response to hydrochlorothiazide in absorptive hypercalciuria. J Urol. 1987;137(6):1104-9.
Arrabal Martín M, Lancina Martín JA. Tratamiento médico de la enfermedad litiásica. En: Criterios clínicos y tratamiento actual de la litiasis urinaria. Madrid: Asociación Española de Urología, 1990; p. 91-111.
Perry HM 3rd, Fallon MD, Bergfeld M, Teitelbaum SL, Avioli LV. Osteoporosis in young men: a syndrome of hypercalciuria and accelerated bone turnover. Arch Intern Med. 1982;142(7):1295-8.
Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol. 2003;169(2):465-9.
Aubin R, Ménard P, Lajeunesse D. Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996;50(5):1476-82.
Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000;109(5):362-70.
Hall TJ. Schaueblin M. Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro. Calcif Tissue Int. 1994;55:266-8.
Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric osteoporotic men treated with hydrochlorothiazide. Ann Int Med. 1999;130:658-60.
